According to a story in Fierce Pharma, France may approve a measure to allow substitution with biosimilars. If this is enacted, then France will become the first European nation to allow this. Needless to say, Big Pharma players like Sanofi, Roche and Amgen are not in support and have turned on their lobbying efforts to block the move.
This measure could (according to sources) could save France between $690 M and $1.4 B in drug costs. This will be very interesting to watch as I have contended that Governments concerned with rising health care costs will be highly motivated to ensure biosimilars succeed in the market. This, despite any pushback from innovator drug companies that claim that the very complex nature of biologics make them extremely hard to duplicate -- and therefore should not be substituted like a small molecule generic might.
I still think biosimilars are coming and there won't be much than can be done to block them from their appointed rounds.
Posted by Bruce Lehr April 14th 2014.